Clinical Trial Update: An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies [Phase 3]

View source ↗

Summary

This document reports results from an extension study of tocilizumab in rheumatoid arthritis patients who completed core phase 3 trials; results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2014-09-30